The short version of synaptic plasticity fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
He served as an Automatic Tracking Radar repairman, rising to the rank of airman first class. After serving from 1955 to 1959, he moved to Los Angeles and took acting classes at the Pasadena Playhouse. He also studied theater arts at Los Angeles City College, where a teacher encouraged him to embark on a dance career.
== Governmental regulation and promotion == Most countries place dietary supplements in a special category under the general umbrella of foods, not drugs. As a result, the manufacturer, and not the government, has the responsibility of ensuring that its dietary supplement products are safe before they are marketed. Regulation of supplements varies widely by country. In the United States, a dietary supplement is defined under the Dietary Supplement Health and Education Act of 1994. There is no FDA approval process for dietary supplements, and no requirement that manufacturers prove the safety or efficacy of supplements introduced before 1994. The Food and Drug Administration must rely on its Adverse Event Reporting System to monitor adverse events that occur with supplements. In 2007, the US Code of Federal Regulations (CFR) Title 21, part III took effect, regulating Good Manufacturing Practices (GMPs) in the manufacturing, packaging, labeling, or holding operations for dietary supplements. Even though product registration is not required, these regulations mandate production and quality control standards (including testing for identity, purity and adulterations) for dietary supplements. In the United States, the United States Pharmacopeia (USP) sets standards for the most commonly used vitamins and preparations thereof. Likewise, monographs of the European Pharmacopoeia (Ph.Eur.) regulate aspects of identity and purity for vitamins on the European market.
On June 9, 2014, Sanders sponsored the Veterans' Access to Care through Choice, Accountability, and Transparency Act of 2014 to reform the Department of Veterans Affairs in the wake of the Veterans Health Administration scandal of 2014. He worked with Senator John McCain, who co-sponsored the bill. His bill was incorporated into the House version of the bill, which passed both chambers on July 31, 2014, and was signed into law by President Obama on August 7, 2014.
Also known as mediastinal emphysema to divers, pneumomediastinum is a volume of gas inside the mediastinum, the central cavity in the chest between the lungs and surrounding the heart and central blood vessels, usually formed by gas escaping from the lungs as a result of lung rupture. Gas bubbles escaping from a ruptured lung can travel along the outside of bronchioles and blood vessels until they reach the mediastinal cavity round the heart, major blood vessels, oesophagus and trachea. Gas trapped in the mediastinum expands as the diver continues to rise. The pressure of the trapped gas may cause intense pain inside the rib cage and in the shoulders, and the gas may compress the respiratory passageways, making breathing difficult, and collapse blood vessels. Symptoms range from pain under the sternum, shock, shallow breathing, unconsciousness, respiratory failure, and associated cyanosis. The gas will usually be absorbed by the body over time, and when the symptoms are mild, no treatment may be necessary. Otherwise it may be vented through a hypodermic needle inserted into the mediastinum. Recompression is not usually indicated.
Sources: en.wikipedia.org
Other prominent Han Chinese who have made notable contributions the development and growth of modern science and technology include the medical researcher, physician, and virologist David Ho, who was one of the first scientists to propose that AIDS was caused by a virus, thus subsequently developing combination antiretroviral therapy to combat it. In recognition of his medical contributions, Ho was named Time magazine Person of the Year in 1996. The medical researcher and transplant surgeon Patrick Soon-Shiong is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is also well known for performing the first whole-pancreas transplant and he developed and first performed the experimental Type 1 diabetes-treatment known as encapsulated-human-islet transplant, and the "first pig-to-man islet-cell transplant in diabetic patients." The physician and physiologist Thomas Ming Swi Chang is the inventor of the world's first artificial cell made from a permeable plastic sack that would effectively carry hemoglobin around the human circulatory system. Chang is also noteworthy for his development of charcoal-filled cells to treat drug poisoning in addition to the discovery of enzymes carried by artificial cells as a medical tool to correct the faults within some metabolic disorders.
Np(V) will also react efficiently in pH levels greater than 5.5 if there are no carbonates present and in these conditions it has also been observed to readily bond with quartz. It has also been observed to bond well with goethite, ferric oxide colloids, and several clays including kaolinite and smectite. Np(V) does not bond as readily to soil particles in mildly acidic conditions as its fellow actinides americium and curium by nearly an order of magnitude. This behavior enables it to migrate rapidly through the soil while in solution without becoming fixed in place, contributing further to its mobility. Np(V) is also readily absorbed by concrete, which because of the element's radioactivity is a consideration that must be addressed when building nuclear waste storage facilities. When absorbed in concrete, it is reduced to Np(IV) in a relatively short period of time. Np(V) is also reduced by humic acids if they are present on the surface of goethite, hematite, and magnetite. Np(IV) is less mobile and efficiently adsorbed by tuff, granodiorite, and bentonite; although uptake by the latter is most pronounced in mildly acidic conditions. It also exhibits a strong tendency to bind to colloidal particulates, an effect that is enhanced when in surface soil with high clay content. The behavior provides an additional aid in the element's observed high mobility.
The thiazolidinediones , abbreviated as TZD, also known as glitazones after the prototypical drug ciglitazone, are a class of heterocyclic compounds consisting of a five-membered C3NS ring. The term usually refers to a family of drugs used in the treatment of diabetes mellitus type 2 that were introduced in the late 1990s. As of 2024, there are two FDA-approved drugs in this class, pioglitazone and rosiglitazone.
Sources: en.wikipedia.org
On 19 June 2024, she received an honorary doctorate from the University of Cambridge in recognition of her achievements in chemistry. In 2024, she was inducted into the National Academy of Inventors. She has been awarded 13 honorary doctorates including the Weizmann Institute of Science, Aarhus University Denmark, University of Kent, the University of York, and the University of Bristol. On 10 August 2025, Robinson appeared on BBC Radio 4's Desert Island Discs.
the vaccination program is not successful in eradicating the disease, on the contrary, it will remain endemic, although at lower levels than the case of absence of vaccinations. This means that the mathematical model suggests that for a disease whose basic reproduction number may be as high as 18 one should vaccinate at least 94.4% of newborns in order to eradicate the disease.
=== January === 1 January Helen Hogan, educator (Hillmorton High School, WEA), editor of poetry anthologies, and Māori studies scholar (born 1923). Lyn Fleming, Police senior sergeant and first policewoman in New Zealand to be killed in the line of duty (born 1963). 2 January – Lex Clark, Olympic rower (1964) (born 1943). 3 January Kate Coolahan, commercial artist, fashion illustrator, printmaker, and design educator (Wellington Polytechnic) (born 1929). Dame Tariana Turia, politician, Labour list MP (1996–2002), MP for Te Tai Hauāuru (2002–2014), co-leader of the Māori Party (2004–2014), Minister for the Community and Voluntary Sector (2003–2004, 2008–2011), Minister for Disability Issues (2009–2014), Minister for Whānau Ora (2010–2014) (born 1944). 5 January Philippa Blair, artist (born 1945). Lou Robinson, structural engineer and heritage advocate (born 1943). 7 January – Arthur Pomeroy, classical scholar (Victoria University of Wellington), chess player and administrator (born 1953). 18 January – Russell Marshall, politician and diplomat, MP for Wanganui (1972–1990), Minister of Education (1984–1987), Minister of Foreign Affairs (1987–1990), chancellor of Victoria University of Wellington (2000–2002), High Commissioner to the United Kingdom (2002–2005) (born 1936). 19 January – David Johnston, disaster researcher (Massey University) (born 1966). 20 January – Richard Hipa, Niuean public servant and politician, Secretary of Government (2008–2017), Member of the Niue Assembly (2020–2023) (born 1957). 21 January Diana Beaglehole, historian (born 1938).
High-performance liquid chromatography or high-pressure liquid chromatography is a form of chromatography applying high pressure to drive the solutes through the column faster. This means that the diffusion is limited and the resolution is improved. The most common form is "reversed phase" HPLC, where the column material is hydrophobic. The proteins are eluted by a gradient of increasing amounts of an organic solvent, such as acetonitrile. The proteins elute according to their hydrophobicity. After purification by HPLC the protein is in a solution that only contains volatile compounds, and can easily be lyophilized. HPLC purification frequently results in denaturation of the purified proteins and is thus not applicable to proteins that do not spontaneously refold.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.